"Progenza includes secretions from MSCs that improves viability and functionality of the cells during the freezing and thawing process. Regeneus has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone."
RGS's secretions technology may turn out to be a unique product platform in regenerative medicine, and probably the key reason why AGC did a JV deal with Regeneus.
REG's secretions technology came in 2015 via a collaboration with Macquarie University.
http://www.mq.edu.au/newsroom/2015/...n-the-door-to-next-generation-cell-therapies/
Ann: Positive clinical trial results for Progenza, page-13
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.579M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6637 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 4968 | 2 |
View Market Depth
| Last trade - 16.12pm 13/09/2024 (20 minute delay) ? |
| CMB (ASX) Chart |
Day chart unavailable